Document Detail

Aprotinin in cardiac surgery patients: is the risk worth the benefit?
MedLine Citation:
PMID:  19782574     Owner:  NLM     Status:  In-Process    
BACKGROUND: Aprotinin is the only Food and Drug Administration-approved agent to reduce haemorrhage related to cardiac surgery and its safety and efficacy has been extensively studied. Our study sought to compare the efficacy, early and late mortality and major morbidity associated with aprotinin compared with e-aminocaproic acid (EACA) in cardiac surgery operations. METHODS: Between January 2002 and December 2006, 2101 patients underwent coronary artery bypass grafting (CABG), valve surgery or CABG and valve surgery in our institution with the use of aprotinin (1898 patients) or EACA (203 patients). Logistic regression and propensity score analysis were used to adjust for imbalances in the patients' preoperative characteristics. The propensity score-adjusted sample included 570 patients who received aprotinin and 114 who received EACA (1-5 matching). RESULTS: Operative mortality was higher in the aprotinin group in univariate (aprotinin 4.3% vs EACA 1%, p=0.023) but not propensity score-adjusted multivariate analysis (4% vs 0.9%, p=0.16). In propensity score-adjusted analysis, aprotinin was also associated with a lower rate of blood transfusion (38.8% vs 50%, p=0.04), a lower rate of haemorrhage-related re-exploration (3.7% vs 7.9%, p=0.04) and a higher risk of in-hospital cardiac arrest (3.7% vs 0%, p=0.03) and a marginally but not statistically significantly higher risk of acute renal failure (6.8% vs 2.6%, p=0.09). In Cox proportional hazards regression analysis, the risk of late death was higher in the aprotinin compared to EACA group (hazard ratio=4.33, 95% confidence interval (CI)=1.60-11.67, p=0.004). CONCLUSION: Aprotinin decreases the rate of postoperative blood transfusion and haemorrhage-related re-exploration, but increases the risk of in-hospital cardiac arrest and late mortality after cardiac surgery when compared to EACA. Cumulative evidence suggests that the risk associated with aprotinin may not be worth the haemostatic benefit.
Sotiris C Stamou; Mark K Reames; Eric Skipper; Robert M Stiegel; Marcy Nussbaum; Rachel Geller; Francis Robicsek; Kevin W Lobdell
Related Documents :
12827584 - Does gender influence resource utilization in patients undergoing off-pump coronary art...
17905274 - Isoflurane, 0.5 minimum alveolar concentration administered through the precardiopulmon...
11426364 - Tranexamic acid in aortic valve replacement.
1510514 - Subcutaneous use of erythropoietin in heart surgery.
24260804 - The efficacy of botulinum toxin treatment for children with a persistent esotropia foll...
21845804 - Factors influencing quality of life after total laryngectomy: a study of 92 patients.
Publication Detail:
Type:  Journal Article     Date:  2009-09-25
Journal Detail:
Title:  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery     Volume:  36     ISSN:  1873-734X     ISO Abbreviation:  Eur J Cardiothorac Surg     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804069     Medline TA:  Eur J Cardiothorac Surg     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  869-75     Citation Subset:  IM    
Department of Thoracic and Cardiovascular Surgery, Carolinas Heart and Vascular Institute, Carolinas Medical Center, Charlotte, NC 28203, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Comment In:
Eur J Cardiothorac Surg. 2009 Nov;36(5):875-6   [PMID:  19595607 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
Next Document:  UVA and UVB radiation-induced oxidation products of quercetin.